Drug intelligence / Profile preview

aplitabart

Development stage: Discontinued
Lead developer: IGM Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Aplitabart is a recombinant pentameric immunoglobulin M (IgM) monoclonal antibody that acts as an agonist of human death receptor type 5 (DR5), also known as tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAILR2). By binding to DR5, aplitabart activates pro-apoptotic signaling pathways in cancer cells, leading to cell death. It was developed primarily for the treatment of solid and hematologic malignancies including colorectal cancer and various lymphomas. The drug was initially developed by IGM Biosciences and reached phase 1 clinical trials before development was discontinued[1][3][8].

Brand names: aplitabart
Other names: IGM-8444IGM8444IGM 8444

Targets

TNFRSF10B (DR5)

Beyond the preview

Go deeper on aplitabart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aplitabart.

Explore the full profile